Clinical Trials Browser

Phase 2 × INDUSTRY × Castration-resistant Prostate Cancer × Clear all

NCT06227156 2024-05-23

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Phase 2 Recruiting

Castration-resistant Prostate Cancer